E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
34 patients aged between 0 and 3 months parted into 2 groups have to undergo caudal block. Group 1 receive a block with 1ml/kg Naropin 3.75% Group 2 receive a block with 1ml/kg Naropin 3.75% and additional 5mg/kg/h propofol 10mg/ml To evaluate the level of sedation we use the Comfort-B Scale, (a sedation score for children)and the change of heart rate throughout the study period as an expression of the actual sedation and stress
|
|
E.1.1.1 | Medical condition in easily understood language |
30 patients aged between 0 and 3 months parted into 2 groups have to undergo a kind of regioanl anaeshtesia. Aim of the study is to investigate if the patients need further medication for sedation. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Pediatric patients (between 0 and 3 months) do not need further medication for sedation after caudal block |
|
E.2.2 | Secondary objectives of the trial |
There is no change in intra- and postoperative level of sedation and heart rate
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Infants aged between 0 and 3 months (inclusive preterm) • Lower body surgery with planned caudal blockade • Written informed consent given by parents after being provided with detailed information about the nature, risks, and scope of the clinical study • No legal incapacity and/or other circumstances rendering the parents unable to understand the nature, scope and possible consequences of the study
|
|
E.4 | Principal exclusion criteria |
• Parents refusal • Contraindications against a caudal blockade • Coagulopathy in the patients history • Other objections to participate in the study in the opinion of the investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
After caudal block children do not need further medication for surgery. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The level of sedation will be evaluated every 10 minutes using the Comfort B-Scale and the percentage of change of the HR will be recorded. These measurements will be continued during the first two postoperative hours. |
|
E.5.2 | Secondary end point(s) |
No change of heart rate and sedation without additional medication for sedation |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The level of sedation will be evaluated every 10 minutes using the Comfort B-Scale and the percentage of change of the HR will be recorded. These measurements will be continued during the first two postoperative hours. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
group I get further medication for sedation |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After discharge of postoperative care unit the study is finished. No further intervention is needed |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |